reviewThe LancetSep 1, 2004Closed access

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

JVJaap VerweijPGPaolo G. CasaliJZJohn ZalcbergALA. LecesnePRPeter Reichardt

Erasmus MC · Erasmus University Rotterdam · +11 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,667
total citations
FWCI
47.53
Percentile
100%
References
19
Citations per year

Authors

12

Topics & keywords

Topics
Keywords
  • Medicine
  • Imatinib
  • Regimen
  • Imatinib mesylate
  • Hazard ratio
  • GiST
  • Internal medicine
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.